BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36255215)

  • 21. Single- and Multifraction Stereotactic Radiosurgery Dose/Volume Tolerances of the Brain.
    Milano MT; Grimm J; Niemierko A; Soltys SG; Moiseenko V; Redmond KJ; Yorke E; Sahgal A; Xue J; Mahadevan A; Muacevic A; Marks LB; Kleinberg LR
    Int J Radiat Oncol Biol Phys; 2021 May; 110(1):68-86. PubMed ID: 32921513
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases.
    Wolf A; Zia S; Verma R; Pavlick A; Wilson M; Golfinos JG; Silverman JS; Kondziolka D
    J Neurooncol; 2016 May; 127(3):607-15. PubMed ID: 26852222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radionecrosis (RN) in patients with brain metastases treated with stereotactic radiosurgery (SRS) and immunotherapy.
    Andring L; Squires B; Seymour Z; Fahim D; Jacob J; Ye H; Marvin K; Grills I
    Int J Neurosci; 2023 Feb; 133(2):186-193. PubMed ID: 33685315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases.
    Rauschenberg R; Bruns J; Brütting J; Daubner D; Lohaus F; Zimmer L; Forschner A; Zips D; Hassel JC; Berking C; Kaehler KC; Utikal J; Gutzmer R; Terheyden P; Meiss F; Rafei-Shamsabadi D; Kiecker F; Debus D; Dabrowski E; Arnold A; Garzarolli M; Kuske M; Beissert S; Löck S; Linn J; Troost EGC; Meier F
    Eur J Cancer; 2019 Mar; 110():11-20. PubMed ID: 30739835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases?
    Colaco RJ; Martin P; Kluger HM; Yu JB; Chiang VL
    J Neurosurg; 2016 Jul; 125(1):17-23. PubMed ID: 26544782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association Between Radiation Necrosis and Tumor Biology After Stereotactic Radiosurgery for Brain Metastasis.
    Miller JA; Bennett EE; Xiao R; Kotecha R; Chao ST; Vogelbaum MA; Barnett GH; Angelov L; Murphy ES; Yu JS; Ahluwalia MS; Suh JH; Mohammadi AM
    Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1060-1069. PubMed ID: 27742540
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors associated with radiation necrosis and intracranial control in patients treated with immune checkpoint inhibitors and stereotactic radiotherapy.
    Hall J; Lui K; Tan X; Shumway J; Collichio F; Moschos S; Sengupta S; Chaudhary R; Quinsey C; Jaikumar S; Forbes J; Andaluz N; Zuccarello M; Struve T; Vatner R; Pater L; Breneman J; Weiner A; Wang K; Shen C
    Radiother Oncol; 2023 Dec; 189():109920. PubMed ID: 37769968
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
    Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
    J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.
    Qian JM; Yu JB; Kluger HM; Chiang VL
    Cancer; 2016 Oct; 122(19):3051-8. PubMed ID: 27285122
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of immune checkpoint inhibitors in combination with stereotactic radiosurgery for patients with brain metastases from renal cell carcinoma: inverse probability of treatment weighting using propensity scores.
    Yomo S; Oda K; Oguchi K
    J Neurosurg; 2023 Jun; 138(6):1591-1599. PubMed ID: 36308485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repeat stereotactic radiosurgery as salvage therapy for locally recurrent brain metastases previously treated with radiosurgery.
    McKay WH; McTyre ER; Okoukoni C; Alphonse-Sullivan NK; Ruiz J; Munley MT; Qasem S; Lo HW; Xing F; Laxton AW; Tatter SB; Watabe K; Chan MD
    J Neurosurg; 2017 Jul; 127(1):148-156. PubMed ID: 27494815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases.
    Frakes JM; Figura NB; Ahmed KA; Juan TH; Patel N; Latifi K; Sarangkasiri S; Strom TJ; Chinnaiyan P; Rao NG; Etame AB
    J Neurosurg; 2015 Nov; 123(5):1261-7. PubMed ID: 26140482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stereotactic radiosurgery for melanoma brain metastases: Concurrent immune checkpoint inhibitor therapy associated with superior clinicoradiological response outcomes.
    Shanker MD; Garimall S; Gatt N; Foley H; Crowley S; Le Cornu E; Muscat K; Soon W; Atkinson V; Xu W; Watkins T; Huo M; Foote MC; Pinkham MB
    J Med Imaging Radiat Oncol; 2022 Jun; 66(4):536-545. PubMed ID: 35343063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment.
    Anderson ES; Postow MA; Wolchok JD; Young RJ; Ballangrud Å; Chan TA; Yamada Y; Beal K
    J Immunother Cancer; 2017 Oct; 5(1):76. PubMed ID: 29037215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of symptomatic radiation necrosis in patients treated with stereotactic radiosurgery for brain metastases.
    Sayan M; Şahin B; Mustafayev TZ; Kefelioğlu EŞS; Vergalasova I; Gupta A; Balmuk A; Güngör G; Ohri N; Weiner J; Karaarslan E; Özyar E; Atalar B
    Neurocirugia (Astur : Engl Ed); 2021; 32(6):261-267. PubMed ID: 34743823
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concurrent Radiosurgery and Immune Checkpoint Inhibition: Improving Regional Intracranial Control for Patients With Metastatic Melanoma.
    Murphy B; Walker J; Bassale S; Monaco D; Jaboin J; Ciporen J; Taylor M; Dai Kubicky C
    Am J Clin Oncol; 2019 Mar; 42(3):253-257. PubMed ID: 30557166
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases.
    Ahmed KA; Freilich JM; Sloot S; Figura N; Gibney GT; Weber JS; Sarangkasiri S; Chinnaiyan P; Forsyth PA; Etame AB; Rao NG
    J Neurooncol; 2015 Mar; 122(1):121-6. PubMed ID: 25519302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factors.
    Sneed PK; Mendez J; Vemer-van den Hoek JG; Seymour ZA; Ma L; Molinaro AM; Fogh SE; Nakamura JL; McDermott MW
    J Neurosurg; 2015 Aug; 123(2):373-86. PubMed ID: 25978710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of Adverse Radiation Effect in Brain Metastasis Patients Treated With Stereotactic Radiosurgery and Immune Checkpoint Inhibitor Therapy.
    Helis CA; Hughes RT; Glenn CW; Lanier CM; Masters AH; Dohm A; Ahmed T; Ruiz J; Triozzi P; Gondal H; Cramer CK; Tatter SB; Laxton AW; Xing F; Lo HW; Su J; Watabe K; Wang G; Whitlow CT; Chan MD
    Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):295-303. PubMed ID: 32615262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases.
    Parsai S; Miller JA; Juloori A; Chao ST; Kotecha R; Mohammadi AM; Ahluwalia MS; Murphy ES; Barnett GH; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
    J Neurosurg; 2019 Feb; 132(2):503-511. PubMed ID: 30738402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.